Do statins cause cancer? A meta-analysis of large randomized clinical trials

American Journal of Medicine

Volumn 110, Issue 9, 2001, Pages 716-723

  Bjerre, Lise M ^a   LeLorier, Jacques ^b  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STATIN;

ADULT; AGED; CANCER; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0035876762     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00705-7     Document Type: Review

References (57)

1. Classical risk factors and emerging elements in the risk profile for coronary artery disease
2. State-of-the-art update and review: Clinical trials of lipid-lowering agents
3. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study
4. Risk factor modification: Rationale for management of dyslipidemia
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study
10. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials
11. Carcinogenicity of lipid-lowering drugs
12. Colon cancer and blood-cholesterol
13. Cancer incidence by levels of cholesterol
14. Cholesterol and noncardiovascular mortality
15. The relationship of serum cholesterol to the incidence of cancer in Evans County, Georgia
16. Serum total cholesterol and mortality in a Japanese population
17. Cholesterol and mortality in New Zealand Maoris
18. Report of the conference on low blood cholesterol: Mortality associations
19. Dietary lipids and the low blood cholesterol-cancer association
20. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer
21. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
22. The Helsinki Heart Study: An 8.5-year safety and mortality follow-up
23. Low serum cholesterol and the risk of cancer: An analysis of the published prospective studies
24. Assessing possible hazards of reducing serum cholesterol
25. Cholesterol lowering with statin drugs, risk of stroke, and total mortality
26. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement
27. Bias in meta-analytic research
28. Large-scale randomized evidence: Large simple trials and overviews of trials
29. Equivalence trials
30. Beta blockade during and after myocardial infarction: An overview of the randomized trials
31. Meta-analysis in clinical trials
32. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
33. Cholesterol, primary and secondary prevention, and all-cause mortality
34. The practice of meta-analysis
35. Meta-analysis: Science or religion?
36. Meta-analysis: A review of pros and cons
37. Issues in comparisons between meta-analyses and large trials
38. Can meta-analysis be trusted?
39. Meta-analysis: Statistical alchemy for the 21st century
40. Large-scale randomized evidence: Large, simple trials and overviews of trials. Discussion: A clinician's perspective on meta-analyses
41. Passive smoking, coronary heart disease, and meta-analysis
42. Discrepancies between meta-analyses and subsequent large randomized, controlled trials
43. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction
44. A coronary primary prevention study of Scottish men aged 45-64 years: Trial design
45. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events trial (CARE)
46. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
47. Design, rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
48. Serum cholesterol and cancer risk: An epidemiologic perspective
49. Does lowering cholesterol cause cancer?
50. Systematic review on the risk and benefit of different cholesterol-lowering interventions
51. Cholesterol reduction yields clinical benefit. A new look at old data
52. Cholesterol reduction and its impact on coronary artery disease and total mortality
53. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease
54. Cholesterol reduction yields clinical benefit: Impact of statin trials
55. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study
56. Protocol for a prospective collaborative overview of all current and planned randomized trias of cholesterol treatment regimens
57. Prospective meta-analysis of cholesterol-lowering studies